O	0	6	Impact
O	7	9	of
O	10	15	young
O	16	19	age
O	20	22	on
O	23	28	local
O	29	36	control
O	37	42	after
B-intervention	43	50	partial
I-intervention	51	57	breast
I-intervention	58	69	irradiation
O	70	72	in
B-ethinicity	73	81	Japanese
B-eligibility	82	90	patients
I-eligibility	91	95	with
I-eligibility	96	101	early
I-eligibility	102	107	stage
I-eligibility	108	114	breast
I-eligibility	115	121	cancer
O	121	122	.

O	123	130	Partial
O	131	137	breast
O	138	149	irradiation
O	150	151	(
O	151	154	PBI
O	154	155	)
O	156	158	is
O	159	161	an
O	162	173	alternative
O	174	176	to
B-control	177	182	whole
I-control	183	189	breast
I-control	190	201	irradiation
I-control	202	203	(
I-control	203	206	WBI
I-control	206	207	)
O	208	211	for
O	212	218	breast
O	218	219	-
O	219	229	conserving
O	230	237	therapy
O	238	239	(
O	239	242	BCT
O	242	243	)
O	243	244	.

O	245	246	A
O	247	257	randomised
O	258	263	phase
O	264	265	3
O	266	271	trial
O	272	284	demonstrated
O	285	289	that
O	290	293	PBI
O	294	299	using
O	300	313	multicatheter
O	314	327	brachytherapy
O	328	331	had
O	332	334	an
O	335	345	equivalent
O	346	350	rate
O	351	353	of
O	354	359	local
O	360	370	recurrence
O	370	371	,
O	372	379	disease
O	379	380	-
O	380	384	free
O	385	393	survival
O	393	394	,
O	395	398	and
O	399	406	overall
O	407	415	survival
O	416	418	as
O	419	427	compared
O	428	430	to
O	431	434	WBI
O	434	435	.

O	436	443	However
O	443	444	,
O	445	452	limited
O	453	457	data
O	458	461	are
O	462	471	available
O	472	474	on
O	475	478	PBI
O	479	487	efficacy
O	488	491	for
O	492	497	young
O	498	506	patients
O	507	511	with
O	512	518	breast
O	519	525	cancer
O	525	526	.

O	527	529	We
O	530	539	evaluated
O	540	551	consecutive
O	552	560	patients
O	561	565	with
O	566	569	Tis
O	569	570	-
O	570	571	2
O	572	573	(
O	573	574	â‰¤
O	575	576	3
O	577	579	cm
O	579	580	)
O	581	583	N0
O	583	584	-
O	584	585	1
O	586	592	breast
O	593	599	cancer
O	600	603	who
O	604	613	underwent
O	614	617	BCT
O	617	618	.

O	619	622	For
O	623	626	PBI
O	626	627	,
O	628	636	patients
O	637	645	received
O	646	658	radiotherapy
O	659	664	using
O	665	678	multicatheter
O	679	692	brachytherapy
O	693	695	in
O	696	698	an
O	699	710	accelerated
O	711	717	manner
O	718	722	with
O	723	724	a
O	725	729	dose
O	730	732	of
O	733	735	32
O	736	738	Gy
O	739	741	in
O	742	747	eight
O	748	757	fractions
O	758	762	over
O	763	764	5
O	764	765	-
O	765	766	6
O	767	771	days
O	771	772	.

O	773	776	For
O	777	780	WBI
O	780	781	,
O	782	790	patients
O	791	799	received
O	800	802	an
O	803	811	external
O	812	816	beam
O	817	826	radiation
O	827	834	therapy
O	835	839	that
O	840	843	was
O	844	851	applied
O	852	854	to
O	855	858	the
O	859	865	entire
O	866	872	breast
O	873	877	with
O	878	879	a
O	880	885	total
O	886	890	dose
O	891	893	of
O	894	896	50
O	897	899	Gy
O	900	902	in
O	903	912	fractions
O	913	915	of
O	916	917	2
O	918	920	Gy
O	921	924	for
O	925	926	5
O	927	932	weeks
O	932	933	.

B-total-participants	934	937	Two
I-total-participants	938	945	hundred
I-total-participants	946	953	seventy
I-total-participants	953	954	-
I-total-participants	954	958	four
O	959	967	patients
O	968	972	with
O	973	976	278
O	977	984	lesions
O	985	993	received
O	994	997	PBI
O	997	998	;
B-intervention-participants	999	1002	190
O	1003	1011	patients
O	1012	1016	with
B-control-participants	1017	1020	193
O	1021	1028	lesions
O	1029	1037	received
O	1038	1041	WBI
O	1041	1042	.

O	1043	1051	Patients
O	1052	1056	aged
B-age	1057	1058	<
I-age	1058	1060	50
I-age	1061	1066	years
O	1067	1076	including
B-intervention-participants	1077	1079	98
O	1080	1085	women
O	1086	1090	with
O	1091	1093	99
O	1094	1101	lesions
O	1102	1111	receiving
O	1112	1115	PBI
O	1116	1119	and
B-control-participants	1120	1122	85
O	1123	1128	women
O	1129	1133	with
O	1134	1136	85
O	1137	1144	lesions
O	1145	1154	receiving
O	1155	1158	WBI
O	1159	1163	were
O	1164	1172	selected
O	1172	1173	.

B-outcome	1174	1185	Ipsilateral
I-outcome	1186	1192	breast
I-outcome	1193	1198	tumor
I-outcome	1199	1209	recurrence
I-outcome	1210	1214	rate
O	1215	1218	was
B-iv-bin-percent	1219	1220	3
I-iv-bin-percent	1220	1221	.
I-iv-bin-percent	1221	1222	0
O	1223	1226	and
B-cv-bin-percent	1227	1228	2
I-cv-bin-percent	1228	1229	.
I-cv-bin-percent	1229	1230	4
I-cv-bin-percent	1231	1232	%
O	1233	1235	by
O	1236	1239	PBI
O	1240	1243	and
O	1244	1247	WBI
O	1247	1248	,
O	1249	1261	respectively
O	1262	1263	(
O	1263	1264	P
O	1265	1266	=
O	1267	1268	0
O	1268	1269	.
O	1269	1271	99
O	1271	1272	)
O	1272	1273	.

O	1274	1279	There
O	1280	1283	was
O	1284	1286	no
O	1287	1298	significant
O	1299	1309	difference
O	1310	1312	in
O	1313	1314	4
O	1314	1315	-
O	1315	1319	year
O	1320	1331	probability
O	1332	1334	of
B-outcome	1335	1342	disease
I-outcome	1342	1343	-
I-outcome	1343	1347	free
I-outcome	1348	1356	survival
O	1357	1358	(
B-iv-bin-percent	1358	1360	97
I-iv-bin-percent	1360	1361	.
I-iv-bin-percent	1361	1362	6
O	1363	1366	and
B-cv-bin-percent	1367	1369	91
I-cv-bin-percent	1369	1370	.
I-cv-bin-percent	1370	1371	4
I-cv-bin-percent	1372	1373	%
O	1374	1377	for
O	1378	1381	PBI
O	1382	1385	and
O	1386	1389	WBI
O	1389	1390	,
O	1391	1403	respectively
O	1403	1404	;
O	1405	1406	P
O	1407	1408	=
O	1409	1410	0
O	1410	1411	.
O	1411	1413	87
O	1413	1414	)
O	1414	1415	.

O	1416	1420	This
O	1421	1423	is
O	1424	1427	the
O	1428	1433	first
O	1434	1440	report
O	1441	1443	of
O	1444	1447	PBI
O	1448	1456	efficacy
O	1457	1459	in
O	1460	1465	young
O	1466	1474	patients
O	1475	1477	in
B-location	1478	1482	Asia
O	1482	1483	.

O	1484	1492	Although
O	1493	1495	it
O	1496	1498	is
O	1499	1500	a
O	1501	1514	nonrandomized
O	1515	1528	retrospective
O	1529	1534	chart
O	1535	1541	review
O	1542	1544	of
O	1545	1546	a
O	1547	1552	small
O	1553	1559	cohort
O	1560	1562	of
O	1563	1571	patients
O	1572	1576	with
O	1577	1578	a
O	1579	1589	relatively
O	1590	1595	short
O	1596	1602	follow
O	1602	1603	-
O	1603	1605	up
O	1606	1612	period
O	1612	1613	,
O	1614	1617	PBI
O	1618	1621	may
O	1622	1624	be
O	1625	1626	a
O	1627	1633	better
O	1634	1640	option
O	1641	1645	than
O	1646	1649	WBI
O	1650	1659	following
O	1660	1663	BCS
O	1664	1666	in
O	1667	1671	some
O	1672	1677	young
O	1678	1686	patients
O	1687	1691	with
O	1692	1698	breast
O	1699	1705	cancer
O	1705	1706	.
